Basal Cell Nevus Syndrome clinical trials
The registry lists 35 studies for Basal Cell Nevus Syndrome across more than 10 countries. 4 are recruiting or about to start. 26 of them are mainly about Basal Cell Nevus Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-09.
Get an email when these change. Save the Basal Cell Nevus Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
UCSF Benioff Children's Hospital Oakland (6) · Novartis Pharmaceuticals (4) · Sol-Gel Technologies, Ltd. (4) · Maastricht University Medical Center (3) · Ascend Biopharmaceuticals Ltd (3) · PellePharm, Inc. (2) · Oslo University Hospital (1) · Stanford University (1)
What is being tested here
Drugs under test in Basal Cell Nevus Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Who these studies take
Of the 3 Basal Cell Nevus Syndrome studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (100%) | 3 (100%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 35 studies, recruiting or not: 26% stop at 75 or younger and 6% at 65; 23% take children; 3% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 35 of 35. search them.
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT030502681 country
- Reproductive Options in Inherited Skin DiseasesEnrolling by invitationNCT063303241 country
- Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive CounsellingRecruitingNCT063303501 country
- Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration StudyRecruitingNCT054637571 country
- Nevoid Basal Cell Carcinomas in Gorlin SyndromeCompletedNCT058983471 country
- Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeCompletedNCT06050122Phase 37 countries
- A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCCTerminatedNCT04155190Phase 21 country
- Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell CarcinomaCompletedNCT03467789Phase 11 country
- Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)TerminatedNCT04308395Phase 39 countries
- CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin SyndromeCompletedNCT04893486Phase 22 countries
- Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)CompletedNCT03703310Phase 310 countries
- Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorCompletedNCT04416516Phase 21 country
- Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)SuspendedNCT03208296Phase 1/21 country
- Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic MedulloblastomaCompletedNCT02017964Phase 24 countries
- To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)CompletedNCT00957229Phase 21 country
- Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell CarcinomasCompletedNCT01556009Phase 21 country
- Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the FaceCompletedNCT00489086Phase 21 country
- Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus SyndromeCompletedNCT02157623Not applicable1 country
- Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome PatientsCompletedNCT02762084Phase 21 country
- Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeWithdrawnNCT03767439Phase 2
- Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell CarcinomaTerminatedNCT02303041Phase 21 country
- Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell CarcinomasCompletedNCT02828111Phase 21 country
- A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell CarcinomaCompletedNCT02550678Phase 1/21 country
- Levocarnitine in Treating Patients With Vismodegib-Associated Muscle SpasmsCompletedNCT01893892Not applicable1 country
- Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus SyndromeCompletedNCT02100371Not applicable1 country
- Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)WithdrawnNCT03070691Phase 2/310 countries
- Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy ParticipantsCompletedNCT00433485Phase 1
- LDE225 for Patients With PTCH1 or SMO Mutated TumorsTerminatedNCT02002689Phase 21 country
- Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and BackCompletedNCT00783965Phase 21 country
- A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome PatientsCompletedNCT00961896Phase 22 countries
- Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)CompletedNCT01350115Phase 24 countries
- Development of a Nanosecond Pulsed Electric Field System to Treat Skin CancerCompletedNCT01463709Phase 11 country
- A Clinical Trial of Dermacorder for Detecting Malignant Skin LesionsCompletedNCT010148191 country
- Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.TerminatedNCT00049959Phase 3
- Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk PatientsCompletedNCT005556331 country